Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Olix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly to develop treatments for cardiovascular and ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...

OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.

Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its ...

To develop OliX’s OLX75016 candidate primarily targeting metabolic-associated steatohepatitis (MASH).

SEONGNAM, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and ...